SMLR Quote, Financials, Valuation and Earnings

ClearPoint Neuro has a net margin of -732.34% compared to Semler Scientific's net margin of -71.02%. Semler Scientific's return on equity of -23.56% beat ClearPoint Neuro's return on equity of -73.69%.

Semler Scientific has a consensus price target of $71.00, signalling upside risk potential of 60.2%. On the other hand ClearPoint Neuro has an analysts' consensus of $29.00 which suggests that it could grow by 143.9%. Given that ClearPoint Neuro has higher upside potential than Semler Scientific, analysts believe ClearPoint Neuro is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.330, which suggesting that the stock is 33.038% more volatile than S&P 500. In comparison ClearPoint Neuro has a beta of 1.032, suggesting its more volatile than the S&P 500 by 3.229%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ClearPoint Neuro offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. ClearPoint Neuro pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than ClearPoint Neuro quarterly revenues of $8.5M. Semler Scientific's net income of -$64.7M is lower than ClearPoint Neuro's net income of -$6M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while ClearPoint Neuro's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.59x versus 10.18x for ClearPoint Neuro. Usually stocks with elevated PS ratios are considered overvalued.

VolitionRX has a net margin of -732.34% compared to Semler Scientific's net margin of -2201.34%. Semler Scientific's return on equity of -23.56% beat VolitionRX's return on equity of --.

Semler Scientific has a consensus price target of $71.00, signalling upside risk potential of 60.2%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 467.22%. Given that VolitionRX has higher upside potential than Semler Scientific, analysts believe VolitionRX is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.330, which suggesting that the stock is 33.038% more volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than VolitionRX quarterly revenues of $246.4K. Semler Scientific's net income of -$64.7M is lower than VolitionRX's net income of -$5.4M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.59x versus 35.53x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

Catheter Precision has a net margin of -732.34% compared to Semler Scientific's net margin of -2828.67%. Semler Scientific's return on equity of -23.56% beat Catheter Precision's return on equity of -137.84%.

Semler Scientific has a consensus price target of $71.00, signalling upside risk potential of 60.2%. On the other hand Catheter Precision has an analysts' consensus of -- which suggests that it could grow by 733.68%. Given that Catheter Precision has higher upside potential than Semler Scientific, analysts believe Catheter Precision is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.330, which suggesting that the stock is 33.038% more volatile than S&P 500. In comparison Catheter Precision has a beta of -0.870, suggesting its less volatile than the S&P 500 by 187.02%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. Catheter Precision pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are larger than Catheter Precision quarterly revenues of $143K. Semler Scientific's net income of -$64.7M is lower than Catheter Precision's net income of -$4M. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while Catheter Precision's PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.59x versus 2.76x for Catheter Precision. Usually stocks with elevated PS ratios are considered overvalued.

Xtant Medical Holdings has a net margin of -732.34% compared to Semler Scientific's net margin of 0.18%. Semler Scientific's return on equity of -23.56% beat Xtant Medical Holdings's return on equity of -26.62%.

Semler Scientific has a consensus price target of $71.00, signalling upside risk potential of 60.2%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 137.51%. Given that Xtant Medical Holdings has higher upside potential than Semler Scientific, analysts believe Xtant Medical Holdings is more attractive than Semler Scientific.

Semler Scientific has a beta of 1.330, which suggesting that the stock is 33.038% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

Semler Scientific has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Semler Scientific pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

Semler Scientific quarterly revenues are $8.8M, which are smaller than Xtant Medical Holdings quarterly revenues of $32.9M. Semler Scientific's net income of -$64.7M is lower than Xtant Medical Holdings's net income of $58K. Notably, Semler Scientific's price-to-earnings ratio is 8.32x while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Semler Scientific is 7.59x versus 0.83x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.